The William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine talked about the ongoing evolution of multiple sclerosis diagnostic criteria and the importance of comprehensive testing to guide early intervention and improve outcomes. [WATCH TIME: 5 minutes]
The William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine discussed the newly updated multiple sclerosis criteria, highlighting their focus on probabilistic assessment, advanced technology integration, and early intervention to improve patient care.
The director of the myasthenia gravis clinic at Yale University discussed the therapeutic potential of inebilizumab, an FDA-approved treatment for NMOSD, in myasthenia gravis, based on data from the phase 3 MINT study.
The director of Child Neurology and Pediatric Sleep Medicine at Geisinger Janet Weis Children's Hospital talked about how the recent approval of once-nightly sodium oxybate for pediatric narcolepsy enables more effective and manageable treatment options for children and families.
The senior scientist at Sunnybrook Research Institute in Toronto, Ontario, provided clinical insight on his lecture given at AANEM 2024, focusing on the challenges and opportunities of teaching the next generation of practitioners.
The postdoctoral research assistant at Charité University Berlin discussed how the new diagnostic criteria for multiple sclerosis could offer earlier detection, especially in those with overlapping autoimmune conditions, through advanced imaging markers.
The consultant neurologist and senior lecturer at St. Georges Hospital in London, provided commentary on the diagnosis, management, and future research around neuropsychiatric symptoms of Parkinson disease.
The consultant neurologist at Imperial College Healthcare Trust discussed a proposed concept of smoldering disease in multiple sclerosis that covers progressive symptoms that go beyond traditional focal inflammatory activity.
The postdoctoral researcher at Amsterdam University Medical Center talked about a tool that helps assess the likelihood of transitioning to secondary progressive multiple sclerosis, allowing clinicians to make informed treatment decisions in a timely manner.
The director of neurology and neuromuscular medicine at the Children’s Hospital of the King’s Daughters in Norfolk, Virginia, provided clinical perspective on some of the improvements in the everyday life and care of patients with spinal muscular atrophy.
The chief executive officer and chief medical officer at Quince Therapeutics talked about recent findings from the phase 3 ATTeST study assessing EryDex in pediatric patients with ataxia telangiectasia.
The chief medical officer and head of Research & Development at Cognition Therapeutics discussed data from the phase 2 proof-of-concept SHINE study assessing CT1812, a small molecule oligomer antagonist, in early-stage Alzheimer disease.
The CEO and cofounder at Advanced Brain Monitoring talked about a study presented at AAIC 2024 that explored the use of EEG biomarkers to differentiate between Alzheimer disease and frontotemporal dementia.
The personalized medicine lead at Linus Health provided clarity on a new outcome measure that captures various perspectives about what matters to individuals and their brain health.
The director of the Brain Health Observatory at the University of Southern California discussed the potential impact of Alzheimer disease blood tests on reducing clinic wait times and improving the diagnostic process in primary care.
The neurologist and clerkship director at the University of Connecticut provided perspective on the developing role of clerkship directors and the value they provide to neurology departments.
The neurologist at Baptist Health provided context on identifying treatment approaches for varying degrees of migraine, the need to optimize medication use, and when patients may be experiencing more than just migraine.
The director of the Center for Sleep and Cardiovascular Outcomes Research at University of Pittsburgh talked about a phase 3 trial assessing a pharmaceutical treatment, AD109, in sleep apnea.
The director at the Foundation for the National Institutes of Health provided commentary on a recently launched partnership aimed at building a repository of ALS data to advance drug development for the disease.
The head of the MS Center at Methodist Hospitals discussed the need for inclusive and affirming healthcare practices for patients with multiple sclerosis who identify as LGBTQ+.
The Minority Stroke Program, open since 2019, encompasses a group of highly trained stroke experts who provide high quality care and education for minority ethnic patients presenting with stroke.
The pulmonologist at Rush Health and immediate past president of the American Academy of Sleep Medicine provided perspective on some of the intriguing changes to sleep medicine and where the field is headed in the coming years.
The associate professor of neurology at Harvard Medical School talked about results from a recent study that evaluated the efficacy of inebilizumab versus rituximab in treating NMOSD.
The neurologist and neuro-oncologist at the Preston Robert Tisch Brain Tumor Center at Duke University provided clarity on a new analysis of the INDIGO study highlighting treatment benefits of vorasidenib in patients with IDH mutant grade 2 gliomas.
The director of the MedStar Georgetown Headache Center talked about results from an analysis on the DELIVER study assessing response rates of eptinezumab in patients with migraine over an 18-month period.
The associate director, Patient Reported Outcomes, Johnson & Johnson, provided clarity on a poster presentation from AAN 2024 examining the most critical aspects to CIDP disease severity.
The professor of neurology at Mayo Clinic talked about the need for comprehensive testing, careful consideration of criteria for diagnosis, and effective treatment in MOG antibody-associated disease.
The head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center provided commentary on the need to properly diagnose Lennox-Gastaut syndrome and the negative downstream impacts of misdiagnosis or underdiagnosing patients.
The executive vice president and chief research officer of the Muscular Dystrophy Association shared her reaction to the recent FDA approval of givinostat for Duchenne muscular dystrophy.
The associate professor of neurology at the University of Naples discussed a recently enrolled study assessing the use of dimethyl fumarate, an approved therapy for relapsing MS and psoriasis, in patients with Friedreich ataxia.
